CCR Clinical Trials at NIH: Clinical Research: Search for Clinical Trials at NIH

The NCI Center for Cancer Research (CCR) conducts more than 150 cancer clinical trials at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. Cancer clinical trials that take place at the NIH Clinical Center are open to patients with cancer, regardless of where they live in the United States.

Go to Search Page

There are 22 clinical trials at NIH that match your search criteria

Cancer by type/disease: Brain Tumor

Trial and Protocol Number Brain Tumor	Principal Investigator	Referral Contact
Phase II
A Phase II Study of TRC105 in Patients With Recurrent Glioblastoma (GBM) NCI-13-C-0048, NCT01757652	Joohee Sul 301-594-9349	Tracy Cropper 301-402-6298 Toll free: 866-251-9686 tcropper@mail.nih.gov
A Phase II Randomized Trial of Lenalidomide in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas NCI-12-C-0136, NCT01553149	Katherine E. Warren 301-496-4256	Linda Ellison 301-496-8009 ellisonl@mail.nih.gov
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas NCI-09-C-0222, NCT00995007	Katharine McNeill 301-443-3441	Tracy Cropper 301-402-6298 Toll free: 866-251-9686 tcropper@mail.nih.gov
A Phase II Clinical Trial of the Histone Deacetylase Inhibitor Valproic Acid in Combination With Temodar and Radiation Therapy in Patients With High Grade Gliomas NCI-06-C-0112, NCT00302159	Kevin A. Camphausen 301-496-5457	Sharon L. Smith 301-496-5457 smiths@mail.nih.gov
Phase I/II
PBTC-033 A Phase I/II Study of ABT-888, an Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children With Newly Diagnosed Diffuse Pontine Gliomas (DIPG) NCI-12-C-0213, NCT01514201	Katherine E. Warren 301-496-4256	Linda Ellison 301-496-8009 ellisonl@mail.nih.gov
A Randomized Phase I/II Study of ABT-888 in Combination With Temozolomide in Recurrent (Temozolomide Resistant) Glioblastoma NCI-12-C-0004, NCT01026493	Teri Kreisl 301-402-3423	Tracy Cropper 301-402-6298 Toll free: 866-251-9686 tcropper@mail.nih.gov
A Phase I/II Study of the Safety and Feasibility of Administering T Cells Expressing Anti-EGFRvIII Chimeric Antigen Receptor to Patients With Malignant Gliomas Expressing EGFRvIII NCI-11-C-0266, NCT01454596	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	June A. Kryk 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
Phase I
Phase I Trial of AZD7451, a Tropomyosin-Receptor Kinase (TRK) Inhibitor, For Adults With Recurrent Glioblastoma Multiforme (GBM) NCI-12-C-0005, NCT01468324	Katharine McNeill 301-443-3441	Tracy Cropper 301-402-6298 Toll free: 866-251-9686 tcropper@mail.nih.gov
A Phase I Trial of Peptide-Based Glioma Vaccine IMA950 in Patients With Glioblastoma (GBM) NCI-11-C-0192, NCT01386463	Joohee Sul 301-594-9349	Tracy Cropper 301-402-6298 Toll free: 866-251-9686 tcropper@mail.nih.gov
Phase I and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma NCI-11-C-0191, NCT01386450	Katherine E. Warren 301-496-4256	Linda Ellison 301-496-8009 ellisonl@mail.nih.gov
A Phase I Trial of Lenalidomide and Radiotherapy in Children With Diffuse Intrinsic Pontine Gliomas and High-grade Gliomas NCI-10-C-0219, NCT01226940	Katherine E. Warren 301-496-4256	Linda Ellison 301-496-8009 ellisonl@mail.nih.gov
An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-Grade Glioma NINDS-09-N-0117, NCT00880061	Russell R. Lonser 301-496-5728	Linda Ellison 301-496-8009 ellisonl@mail.nih.gov
No Phase
An Exploratory Study of Biologic and Pathophysiologic Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors NCI-06-C-0219, NCT00401037	Katherine E. Warren 301-496-4256	Linda Ellison 301-496-8009 ellisonl@mail.nih.gov
A Comparative Study of Pediatric CNS Tumor Activity as Assessed by 18F-FDG PET Imaging and Proton Magnetic Resonance Spectroscopic Imaging (1H-MRSI) NCI-03-C-0278, NCT00070512	Katherine E. Warren 301-496-4256	Linda Ellison 301-496-8009 ellisonl@mail.nih.gov
Evaluation of the Natural History of Patients With Tumors of the Central Nervous System NCI-01-C-0070, NCT00458640	Teri Kreisl 301-402-3423	Tracy Cropper 301-402-6298 Toll free: 866-251-9686 tcropper@mail.nih.gov

Trial and Protocol Number Breast Cancer	Principal Investigator	Referral Contact
Phase II
A Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases NCI-12-C-0087, NCT01480583	Susan Bates 301-402-5958	Christine Bryla 301-451-7868 brylacm@mail.nih.gov

Trial and Protocol Number Lymphoma	Principal Investigator	Referral Contact
Phase II
AIDS-Related Primary Central Nervous System Lymphoma: A Phase II Pilot Study of High-Dose Intravenous Methotrexate With Rituximab Leucovorin Rescue and Highly Active Antiretroviral Therapy NCI-06-C-0051, NCT00267865	Robert Yarchoan 301-496-8959	Karen Aleman 301-496-8959 1-800-243-2732 ext. 4 (Toll Free) alemank@mail.nih.gov

Trial and Protocol Number Neurofibroma/Neurofibromatosis	Principal Investigator	Referral Contact
Phase I
A Phase II Study of Everolimus (RAD001) for Children With Neurofibromatosis Type-1 and Chemotherapy-Refractory Radiographic Progressive Low-Grade Gliomas NCI-12-C-0058, NCT00901849	Katherine E. Warren 301-496-4256	Linda Ellison 301-496-8009 ellisonl@mail.nih.gov

Trial and Protocol Number Pediatric Cancers	Principal Investigator	Referral Contact
Phase I
Phase I Study of Temsirolimus in Combination With Irinotecan and Temozolomide in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors NCI-11-C-0053, NCT01141244	Brigitte Widemann 301-496-7387	Pediatric Oncology 301-496-4256 1-877-624-4878 (Toll free)
Phase I Trial and Pharmacokinetic Study of the Oral Platinum Analog Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors NCI-11-C-0047, NCT01259479	Brigitte Widemann 301-496-7387	Pediatric Oncology 301-496-4256 1-877-624-4878 (Toll free)
A Phase 1/2 Study of PF-02341066, An Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children With Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma NCI-10-C-0178, NCT01182896	Brigitte Widemann 301-496-7387	Pediatric Oncology 301-496-4256 1-877-624-4878 (Toll free)

Trial and Protocol Number Solid Tumor	Principal Investigator	Referral Contact
Phase II
Pilot Study of GRN1005 for Resectable Brain Metastases in Patients With Breast Cancer and Non-Small Cell Lung Cancer NCI-12-C-0199, NCT01679743	Susan Bates 301-402-5958	Christine Bryla 301-451-7868 brylacm@mail.nih.gov

For additional studies that may be appropriate for your disease type, please search under Solid Tumor.